Department of Surgical Oncology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas.
Department of Abdominal Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Ann Surg. 2022 Dec 1;276(6):1023-1028. doi: 10.1097/SLA.0000000000004682. Epub 2020 Dec 22.
To identify rates of positive circumferential resection margin (CRM) for colon cancer surgery in the US.
CRM is one of the most important determinants of local control in colorectal cancers. The extent to which CRM involvement exists after colon cancer surgery is unknown.
Colon cancer cases with resection 2010 to 2015 were identified from the National Cancer Data Base. Adjusting for patient and tumor characteristics, comparisons were made between cases with CRM > 1 mm (negative margin) and those with margin involved with tumor or ≤ 1 mm (positive margin, CRM+). Hospital-level analysis was performed, examining observed-to-expected CRM+ rates.
In total, 170,022 cases were identified: 150,291 CRM- and 19,731 CRM+ (11.6%). Pathologic T-category was the greatest predictor of CRM+, with higher rates in pT4(25.8%), pT4A(24.7%), and pT4B(31.5%) versus pT1(4.5%), pT2(6.3%) and pT3 (10.9%, P < 0.001). Within pT4 patients, predictors of CRM+ included signet-ring histology (38.1% vs 26.7% nonmucinous, and 26.9% mucinous adenocarcinoma, P < 0.001), removing < 12 lymph nodes (36.5% vs 26.1% >12, P < 0.001), community facilities (32.7%) versus academic/research (23.6%, P < 0.001), year (30.1% 2010 vs 22.6% 2015, P < 0.001), and hospital volume (24.5% highest quartile vs 32.7% lowest, P < 0.001). Across 1288 hospitals, observed-to-expected ratios for CRM+ ranged from 0 to 7.899; 429 facilities had higher than expected rates.
Overall rate of CRM+ in US colon cancer cases is high. Variation exists across hospitals, with higher than expected rates in many facilities. Although biology is a major influencing factor, CRM+ rates represent an area for multidisciplinary improvement in quality of colon cancer care.
确定美国结肠癌手术中阳性环周切缘(CRM)的比率。
CRM 是结直肠癌局部控制最重要的决定因素之一。结肠癌手术后 CRM 受累的程度尚不清楚。
从国家癌症数据库中确定了 2010 年至 2015 年的结肠癌病例。在调整了患者和肿瘤特征后,比较了 CRM>1mm(阴性切缘)和 CRM 受累或≤1mm(阳性切缘,CRM+)的病例。进行了医院水平分析,检查了观察到的 CRM+率与预期的比率。
共确定了 170022 例病例:150291 例 CRM-和 19731 例 CRM+(11.6%)。病理 T 分期是 CRM+的最大预测因素,pT4(25.8%)、pT4A(24.7%)和 pT4B(31.5%)高于 pT1(4.5%)、pT2(6.3%)和 pT3(10.9%,P<0.001)。在 pT4 患者中,CRM+的预测因素包括印戒细胞组织学(38.1% vs 26.7%非黏液性和 26.9%黏液性腺癌,P<0.001)、切除<12 个淋巴结(36.5% vs 26.1%>12 个,P<0.001)、社区医疗机构(32.7%)与学术/研究机构(23.6%,P<0.001)、年份(30.1%2010 年 vs 22.6%2015 年,P<0.001)和医院容量(24.5%最高四分位数与 32.7%最低四分位数,P<0.001)。在 1288 家医院中,观察到的 CRM+比值范围为 0 至 7.899;429 家医院的比值高于预期。
美国结肠癌病例中 CRM+的总体比率较高。医院之间存在差异,许多医院的比率高于预期。尽管生物学是一个主要的影响因素,但 CRM+的比率代表了提高结肠癌治疗质量的一个多学科改进领域。